Novo Nordisk, the Danish pharma company behind Ozempic and Wegovy, made one very dumb decision a few years ago that will ...

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sandoz Group Ltd with a $51.82 average price target.

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

Leading generic drugmakers have mixed views on President Donald Trump’s repeated threats to impose tariffs on pharmaceutical goods in a bid to push global pharma majors to shift their manufacturing ...

The global Biosimilars Market, valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to advance at a resilient ...

The global Biosimilars Market, valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

Wyost and Jubbonti are interchangeable with Xgeva/Prolia and are approved for all of the same indications in bone cancer and ...

Drugmakers want more clarity from the Trump administration on the potential pharmaceutical tariffs, which some companies warn ...

Generic Drugs Market Size to Reach USD 769.52 Billion by 2033 | Says Cervicorn ConsultingThe generic drugs market size is reaching an estimated value of USD 830.10 billion by 2034 rising from USD 327.

I’m sure someone’s lost their job,” said the CEO of Sandoz, which has now filed to launch a generic GLP-1 drug in Canada next ...

The reason Novo Nordisk is losing patent protection is because it wouldn't pay a couple hundred bucks. In 2019, the Canadian patent office sent a letter saying it hadn't received Novo Nordisk's annual ...